Related Experiment Video
Updated: May 12, 2025
In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase
Published on: November 5, 2021
Statins do not reduce the parasite burden during experimental Trypanosoma cruzi infection
Sarah Razzaq1, Francisco Olmo1,2, Suresh B Lakshminarayana3
1Department of Infection Biology, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Insights
Statins do not reduce Trypanosoma cruzi parasite load in mice, despite potential cardioprotective effects. Systemic concentrations were too low for trypanocidal activity, questioning clinical trials for this purpose.
Area of Science:
- Infectious Diseases
- Pharmacology
- Cardiology
Background:
- Cardiomyopathy is a common complication of Trypanosoma cruzi infection.
- Statins are being investigated for potential cardioprotective and trypanocidal activities against T. cruzi.
Purpose of the Study:
- To evaluate the efficacy of statins in reducing Trypanosoma cruzi parasite load.
- To determine if systemic concentrations of statins achieved in vivo are sufficient for trypanocidal activity.
Main Methods:
- A highly sensitive bioluminescent mouse model of Trypanosoma cruzi infection was used.
- Mice were treated with statins for 5 days.
- Systemic concentrations of statins were measured.
Main Results:
- Statin treatment did not significantly impact parasite load in the mouse model.
- Achieved free systemic concentrations of statins were below the level required for trypanocidal potency.
- No significant reduction in T. cruzi burden was observed.
Conclusions:
- Statins lack significant trypanocidal activity against Trypanosoma cruzi at the tested dosage and duration.
- Current evidence does not support clinical trials investigating the trypanocidal effects of statins in T. cruzi infections.
- Further research may be needed to explore alternative therapeutic strategies for T. cruzi-associated cardiomyopathy.
Abstract:
Cardiomyopathy is the most common pathology associated with Trypanosoma cruzi infection. Reports that statins have both cardioprotective and trypanocidal activity have generated interest in their potential as a therapeutic treatment. Using a highly sensitive bioluminescent mouse model, we show that a 5-day treatment with statins has no significant impact on parasite load. The free systemic concentrations fail to reach the level required for potency. Hence, clinical trials to investigate the trypanocidal activity of statins lack experimental justification.
